Therapy Areas: Inflammatory Diseases
NeoImmuneTech names new president and chief executive officer
3 April 2024 -

NeoImmuneTech Inc (KOSDAQ: 950220), a US-based clinical-stage T cell-focused biopharmaceutical company, announced on Tuesday that it has named Luke Oh, PhD as its new president and chief executive officer (CEO).

Dr Oh is to succeed Dr Se Hwan Yang, PhD. In the new role, Dr. Oh will head the company from its Rockville headquarters and oversee all of the company's Korea operations.

With more than six years of regulatory experience at the US FDA, Dr Oh has also served as vice-president in charge of Regulatory Development at Samsung Bioepis, senior staff fellow at the US FDA Division of Clinical Pharmacology III and Division of Inflammation and Immune Pharmacology, and in various roles in research and development for leading organisations such as Mallinckrodt Pharmaceuticals, Human Genome Sciences and Vertex Pharmaceuticals.